Studies and sources
The evidence cited across Peptide Renewal Serum, described by author, year, and study type. Each link leads to the exact source used in the discussion.
GHK-Cu, skin, and hair
Topical preparations and delivery
Mortazavi, Mohammadi Vadoud, and Moghimi, 2025, BioImpacts. This review of topical GHK preparations discusses skin findings and difficulties delivering the peptide through intact skin. It provides context for cosmetic claims, rather than evidence that every serum has the same effect. Formulation remains part of the question.
Skin remodeling across study settings
Pickart, Vasquez-Soltero, and Margolina, 2015, BioMed Research International. This review of GHK and skin biology brings together cell studies and small topical human studies. It supports discussion of collagen and remodeling while requiring care about which preparation and experimental setting produced each finding.
Collagen production in cultured cells
Maquart and colleagues, 1988, FEBS Letters. The human fibroblast experiment examined collagen synthesis under laboratory conditions. It is foundational mechanistic evidence for interest in GHK-Cu. The endpoint was cellular collagen production, not wrinkle depth or a cosmetic improvement measured in people.
Copper transport through excised skin
Hostynek, Dreher, and Maibach, 2011, Inflammation Research. The skin-layer penetration experiment measured copper passing through and remaining in human skin outside the body over 48 hours. The result concerns copper transport and retention. It does not establish how long an intact peptide or visible benefit persists.
A combination tested for hair counts
Lee and colleagues, 2016, Annals of Dermatology. The six-month controlled hair trial involved 45 men with pattern hair loss. The preparation combined GHK and 5-aminolevulinic acid. Greater hair-count gains than placebo belong to that combination; the study cannot isolate GHK's contribution.
GLOW and its component literature
The wider peptide-therapy evidence
Mendias and Awan, 2026, Sports Medicine. This review of approved and unapproved peptide therapies discusses the field's preclinical findings and limited rigorous human safety evidence. It supplies context for GLOW's ingredients, without establishing the safety or efficacy of the combined blend.
BPC-157 and the human evidence gap
McGuire and colleagues, 2025, Current Reviews in Musculoskeletal Medicine. This BPC-157 narrative review considers musculoskeletal findings and small human pilot studies. A review of one ingredient cannot establish combined GLOW effects or replace a controlled trial of the mixture itself.
Blood-vessel signaling in experimental models
Hsieh and colleagues, 2017, Journal of Molecular Medicine. The BPC-157 vascular-mechanism study used chick, rat, and human cell models to examine blood-vessel-related signaling. These are preclinical findings. They support mechanistic questions, rather than a demonstrated healing benefit or established cancer risk in people.
Melanotan-2 experiments and case reports
Oral pigmentation with later observations
Bonchev, 2026, Life. The oral-pigmentation case report describes changes in one man and follow-up after stopping melanotan II. Cheek and gum pigment followed different courses. A single case cannot estimate frequency or predict another person's recovery time.
A serious kidney event
Peters and colleagues, 2020, CEN Case Reports. The renal-infarction report and review discusses kidney injury possibly associated with melanotan II and proposed mechanisms. Its role here is safety context. Case documentation does not supply an incidence rate or settle causation by itself.
Development of melanocortin medicines
Hadley and Dorr, 2006, Peptides. This historical review of melanocortin therapeutics describes the development of related compounds and clinical questions. It helps distinguish family relationships from substance identity. Approval or evidence for a different compound cannot be transferred to melanotan II.
An early human crossover experiment
Wessells and colleagues, 1998, Journal of Urology. The placebo-controlled erectile-response study involved ten men with psychogenic erectile dysfunction. Its small population, outcome, and transient adverse effects are part of its interpretation. It cannot establish the safety of repeated cosmetic use.
Food motivation in mice
Eliason and colleagues, 2022, Neuropeptides. The mouse food-motivation experiment delivered melanotan II directly into a brain region. Species and route are essential qualifiers. The finding is not evidence for a human appetite treatment or a cosmetic safety profile.
FDA source material
Safety concerns and withdrawn nominations
U.S. Food and Drug Administration, page current as of April 22, 2026. The bulk-substance safety-risk page separates withdrawn nominations from the Category 2 table. Withdrawal does not mean clearance. The safety explanations beside the entries remain important to the discussion of injectable peptides.
Non-injectable GHK-Cu under evaluation
U.S. Food and Drug Administration, list updated May 14, 2026. The 503A bulk-substance category document distinguishes non-injectable GHK-Cu from the injectable entry. Category 1 describes a conditional enforcement policy during evaluation. It is not approval of a medicine, a formulation, or a particular use.